Innovent Biologics, Inc.
1801
Classement en actions
#1153
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Prix de l'action
$11.35
Capitalisation boursière
$19.80B
Changement (1 jour)
1.56%
Changement (1 an)
1.55%
Pays
CN
Échange Innovent Biologics, Inc. (1801)
Catégorie
Healthcare
Ratio P/E pour Innovent Biologics, Inc. (1801)
Ratio P/E au October 2026 TTM : 105.41
Selon les derniers rapports financiers et le cours de l'action de Innovent Biologics, Inc., le ratio P/E actuel (TTM) est de 105.41. À la fin de l’année 2023, le P/E de l’entreprise était de -58.77.
Historique du ratio P/E pour Innovent Biologics, Inc. de 2016 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 105.41 | -117.83% |
| 2024 | -591.18 | 905.86% |
| 2023 | -58.77 | 190.58% |
| 2022 | -20.23 | -3.23% |
| 2021 | -20.90 | -77.80% |
| 2020 | -94.13 | 479.66% |
| 2019 | -16.24 | 1,224.06% |
| 2018 | -1.23 | -95.53% |
| 2017 | -27.44 | -16.62% |
| 2016 | -32.91 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -72.70% |
US
|
|
| -28.36 | -126.90% |
US
|
|
| -24.57 | -123.31% |
AU
|
|
| 30.33 | -71.23% |
NL
|
|
| - | - |
CH
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.